Medical Necessity of Xembify for Nonfamilial Hypogammaglobulinemia

Assessment and Diagnosis

The American Academy of Allergy, Asthma, and Immunology recommends that patients with nonfamilial hypogammaglobulinemia receive immunoglobulin replacement therapy to reduce infection frequency, as seen in this patient with a history of recurrent sinusitis/upper respiratory infections 1, 2
A 47-year-old female patient with established nonfamilial hypogammaglobulinemia has demonstrated clinical benefit with no major infections while on Xembify 7g weekly therapy, indicating effective management of the condition 1

The American College of Allergy, Asthma, and Immunology guidelines support the medical necessity of Xembify for patients with nonfamilial hypogammaglobulinemia who have demonstrated a reduction in bacterial infections since initiation of therapy, as observed in this patient 1, 2
The patient's last documented IgG level of 746 mg/dL is within the normal range, indicating effective therapy, according to the American Academy of Allergy, Asthma, and Immunology 1, 3

Practice parameters for primary immunodeficiency recommend a minimum monitoring frequency of every 6-12 months for patients receiving immunoglobulin replacement therapy, as suggested by the American Academy of Allergy, Asthma, and Immunology 1, 2
The Blood Cancer Journal recommends that clinical response, including reduction in infection frequency, is considered more important than serum levels alone in determining continued therapy for patients with hypogammaglobulinemia 4
Maintaining IgG levels ≥400 mg/dL is recommended for patients with hypogammaglobulinemia, which this patient has achieved based on the most recent measurement, according to the Blood Cancer Journal 4

The American Academy of Allergy, Asthma, and Immunology suggests that the benefits of continuing Xembify therapy include prevention of recurrent infections and maintenance of quality of life, as demonstrated in this patient 1, 2
The risks of discontinuing therapy include potential recurrence of infections and risk of hospitalization, as indicated by the Journal of Allergy and Clinical Immunology 1